Mahasweta Gooptu, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graft vs Host Disease | 27 | 2024 | 3079 | 3.790 |
Why?
|
Hematopoietic Stem Cell Transplantation | 35 | 2024 | 5753 | 3.010 |
Why?
|
Cyclophosphamide | 8 | 2024 | 2234 | 1.240 |
Why?
|
Transplantation Conditioning | 8 | 2024 | 1635 | 1.170 |
Why?
|
Transplantation, Homologous | 13 | 2024 | 4860 | 1.100 |
Why?
|
Tacrolimus | 4 | 2023 | 753 | 1.000 |
Why?
|
Myelodysplastic Syndromes | 5 | 2024 | 1404 | 0.970 |
Why?
|
Leukemia, Myeloid, Acute | 9 | 2024 | 3636 | 0.770 |
Why?
|
Opportunistic Infections | 1 | 2023 | 376 | 0.710 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 273 | 0.650 |
Why?
|
Hematologic Neoplasms | 3 | 2023 | 1926 | 0.630 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 617 | 0.560 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 838 | 0.550 |
Why?
|
Antilymphocyte Serum | 1 | 2018 | 492 | 0.530 |
Why?
|
Oxidative Phosphorylation | 1 | 2017 | 502 | 0.490 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 1434 | 0.460 |
Why?
|
Glycolysis | 1 | 2017 | 838 | 0.430 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2015 | 125 | 0.420 |
Why?
|
Sirolimus | 1 | 2019 | 1540 | 0.390 |
Why?
|
Immunosuppressive Agents | 3 | 2024 | 4215 | 0.380 |
Why?
|
Recovery of Function | 1 | 2019 | 2976 | 0.310 |
Why?
|
Recurrence | 6 | 2023 | 8507 | 0.230 |
Why?
|
Mitochondria | 1 | 2017 | 3677 | 0.230 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
Antigens, CD34 | 1 | 2024 | 656 | 0.200 |
Why?
|
Interleukin-2 | 2 | 2022 | 1895 | 0.200 |
Why?
|
Adult | 26 | 2024 | 223307 | 0.190 |
Why?
|
Busulfan | 2 | 2021 | 264 | 0.180 |
Why?
|
Humans | 48 | 2024 | 766766 | 0.180 |
Why?
|
Vidarabine | 2 | 2021 | 342 | 0.180 |
Why?
|
Acute Disease | 3 | 2020 | 7241 | 0.170 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2022 | 221 | 0.170 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1642 | 0.170 |
Why?
|
BK Virus | 1 | 2020 | 120 | 0.160 |
Why?
|
Transplantation Immunology | 1 | 2021 | 540 | 0.160 |
Why?
|
Treatment Failure | 1 | 2024 | 2659 | 0.150 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 1080 | 0.150 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2017 | 81 | 0.140 |
Why?
|
Myeloablative Agonists | 1 | 2018 | 215 | 0.140 |
Why?
|
Whole-Body Irradiation | 1 | 2018 | 438 | 0.140 |
Why?
|
Immunocompromised Host | 2 | 2019 | 865 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1982 | 0.140 |
Why?
|
Standard of Care | 1 | 2021 | 569 | 0.130 |
Why?
|
Cytomegalovirus | 1 | 2021 | 754 | 0.130 |
Why?
|
Cryopreservation | 1 | 2021 | 727 | 0.130 |
Why?
|
Middle Aged | 18 | 2024 | 223257 | 0.120 |
Why?
|
Aminopterin | 1 | 2015 | 15 | 0.120 |
Why?
|
Retrospective Studies | 13 | 2024 | 81635 | 0.120 |
Why?
|
Symporters | 1 | 2017 | 362 | 0.120 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2015 | 187 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1791 | 0.110 |
Why?
|
Diphtheria Toxin | 1 | 2015 | 253 | 0.110 |
Why?
|
Lymphocyte Activation | 2 | 2022 | 5503 | 0.110 |
Why?
|
Orbital Diseases | 1 | 2015 | 178 | 0.110 |
Why?
|
Compartment Syndromes | 1 | 2015 | 159 | 0.110 |
Why?
|
Orbital Neoplasms | 1 | 2015 | 223 | 0.110 |
Why?
|
Aged | 16 | 2024 | 171343 | 0.100 |
Why?
|
Piperidines | 1 | 2021 | 1663 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1086 | 0.100 |
Why?
|
Hepatitis B Core Antigens | 1 | 2012 | 90 | 0.100 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1320 | 0.100 |
Why?
|
Muscle Proteins | 1 | 2017 | 1160 | 0.100 |
Why?
|
Stromal Cells | 1 | 2017 | 1334 | 0.100 |
Why?
|
Membrane Transport Proteins | 1 | 2017 | 1029 | 0.100 |
Why?
|
Azacitidine | 2 | 2024 | 335 | 0.090 |
Why?
|
Communicable Diseases | 1 | 2019 | 872 | 0.090 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2678 | 0.090 |
Why?
|
Male | 16 | 2024 | 364142 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1946 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2533 | 0.090 |
Why?
|
Female | 16 | 2024 | 396520 | 0.080 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 776 | 0.080 |
Why?
|
Lymphocytes | 1 | 2017 | 2605 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8540 | 0.080 |
Why?
|
Hepatitis B virus | 1 | 2012 | 531 | 0.080 |
Why?
|
Lung Diseases | 1 | 2019 | 1941 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9404 | 0.080 |
Why?
|
Receptors, Cell Surface | 1 | 2017 | 2815 | 0.070 |
Why?
|
Young Adult | 8 | 2024 | 59939 | 0.070 |
Why?
|
Steroids | 2 | 2023 | 936 | 0.070 |
Why?
|
Adolescent | 6 | 2024 | 88904 | 0.070 |
Why?
|
Hepatitis B | 1 | 2012 | 709 | 0.070 |
Why?
|
Immunoconjugates | 1 | 2015 | 976 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2596 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2015 | 1600 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3738 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2022 | 13643 | 0.060 |
Why?
|
Bone Marrow Transplantation | 2 | 2023 | 2730 | 0.060 |
Why?
|
Survival Analysis | 1 | 2018 | 10100 | 0.060 |
Why?
|
Double-Blind Method | 1 | 2018 | 12430 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11061 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2823 | 0.050 |
Why?
|
Hypersensitivity | 1 | 2012 | 1169 | 0.050 |
Why?
|
Child | 2 | 2023 | 80668 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10264 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 100 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2022 | 2210 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11872 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8735 | 0.050 |
Why?
|
Mycophenolic Acid | 1 | 2023 | 349 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 262 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 136 | 0.040 |
Why?
|
Tissue Donors | 2 | 2022 | 2392 | 0.040 |
Why?
|
Forehead | 1 | 2021 | 75 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 897 | 0.040 |
Why?
|
Ohio | 1 | 2021 | 320 | 0.040 |
Why?
|
Graft vs Leukemia Effect | 1 | 2020 | 122 | 0.040 |
Why?
|
Acetates | 1 | 2021 | 314 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2017 | 22248 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2012 | 3618 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2020 | 59550 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 891 | 0.040 |
Why?
|
Lung Diseases, Fungal | 1 | 2019 | 123 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 5690 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6359 | 0.040 |
Why?
|
Cohort Studies | 2 | 2018 | 41710 | 0.040 |
Why?
|
Decision Trees | 1 | 2019 | 508 | 0.030 |
Why?
|
Methotrexate | 1 | 2023 | 1719 | 0.030 |
Why?
|
Progesterone | 1 | 2021 | 752 | 0.030 |
Why?
|
Pleural Effusion | 1 | 2019 | 344 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2021 | 2127 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20708 | 0.030 |
Why?
|
Adenine | 1 | 2021 | 993 | 0.030 |
Why?
|
Incidence | 2 | 2023 | 21525 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 950 | 0.030 |
Why?
|
Quinazolines | 1 | 2021 | 1367 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2021 | 65273 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 834 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11094 | 0.030 |
Why?
|
Antigens, CD | 1 | 2022 | 4032 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2839 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2022 | 2948 | 0.020 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2012 | 293 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1885 | 0.020 |
Why?
|
Conjunctivitis | 1 | 2012 | 153 | 0.020 |
Why?
|
Immunotherapy, Adoptive | 1 | 2021 | 1504 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6512 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3434 | 0.020 |
Why?
|
Animals | 1 | 2021 | 168930 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3070 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9357 | 0.020 |
Why?
|
Respiratory Sounds | 1 | 2012 | 702 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8891 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9346 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4410 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2159 | 0.020 |
Why?
|
Age Factors | 1 | 2024 | 18397 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2012 | 2586 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3432 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4652 | 0.020 |
Why?
|
HIV Infections | 1 | 2012 | 17536 | 0.020 |
Why?
|
India | 1 | 2012 | 2335 | 0.020 |
Why?
|
DNA, Viral | 1 | 2012 | 2201 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9244 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3804 | 0.020 |
Why?
|
Prevalence | 2 | 2012 | 15835 | 0.020 |
Why?
|
Rhinitis | 1 | 2012 | 753 | 0.010 |
Why?
|
RNA, Viral | 1 | 2012 | 2867 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12985 | 0.010 |
Why?
|
Neoplasms | 1 | 2012 | 22350 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 6066 | 0.010 |
Why?
|
United States | 2 | 2021 | 72951 | 0.010 |
Why?
|
Health Surveys | 1 | 2012 | 4055 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 4780 | 0.010 |
Why?
|
Lung | 1 | 2019 | 10067 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6779 | 0.010 |
Why?
|
Risk Factors | 2 | 2020 | 74881 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 24295 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 40149 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 54871 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15416 | 0.010 |
Why?
|
Mutation | 1 | 2012 | 30213 | 0.000 |
Why?
|